KR960701211A - 암 백신을 제조하는 방법(process for preparing cancer vaccines) - Google Patents

암 백신을 제조하는 방법(process for preparing cancer vaccines)

Info

Publication number
KR960701211A
KR960701211A KR1019950703645A KR19950703645A KR960701211A KR 960701211 A KR960701211 A KR 960701211A KR 1019950703645 A KR1019950703645 A KR 1019950703645A KR 19950703645 A KR19950703645 A KR 19950703645A KR 960701211 A KR960701211 A KR 960701211A
Authority
KR
South Korea
Prior art keywords
cancer vaccines
preparing cancer
preparing
vaccines
cancer
Prior art date
Application number
KR1019950703645A
Other languages
English (en)
Korean (ko)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0055693A external-priority patent/AT399656B/de
Priority claimed from DE4326821A external-priority patent/DE4326821A1/de
Application filed filed Critical
Publication of KR960701211A publication Critical patent/KR960701211A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019950703645A 1993-03-19 1995-08-28 암 백신을 제조하는 방법(process for preparing cancer vaccines) KR960701211A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0055693A AT399656B (de) 1993-03-19 1993-03-19 Verfahren zur herstellung von krebsvakzinen
DE4326821A DE4326821A1 (de) 1993-08-10 1993-08-10 Verfahren zur Herstellung von Krebsvakzinen
PCT/EP1994/000859 WO1994021808A1 (fr) 1993-03-19 1994-03-18 Procede de preparation de vaccins anticancereux

Publications (1)

Publication Number Publication Date
KR960701211A true KR960701211A (ko) 1996-02-24

Family

ID=25593140

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703645A KR960701211A (ko) 1993-03-19 1995-08-28 암 백신을 제조하는 방법(process for preparing cancer vaccines)

Country Status (13)

Country Link
EP (1) EP0689604A1 (fr)
JP (1) JPH08507921A (fr)
KR (1) KR960701211A (fr)
CN (1) CN1119459A (fr)
AU (1) AU6427994A (fr)
CA (1) CA2158655A1 (fr)
CZ (1) CZ241795A3 (fr)
FI (1) FI954383A0 (fr)
HU (1) HUT73383A (fr)
NO (1) NO953684L (fr)
NZ (1) NZ263550A (fr)
PL (1) PL311036A1 (fr)
WO (1) WO1994021808A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130121910A (ko) * 2010-12-02 2013-11-06 온코세라피 사이언스 가부시키가이샤 Tomm34 펩티드 및 이를 포함한 백신
WO2019132594A1 (fr) * 2017-12-29 2019-07-04 한양대학교 산학협력단 Feuille cellulaire pour l'administration de gènes

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190290C (fr) * 1994-05-13 2011-07-05 Michael J. Mastrangelo Procede permettant d'induire une reponse immunitaire au moyen de virus vaccinaux recombines
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE4426429A1 (de) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
DE19510344C1 (de) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Verwendung einer Tumorvakzine
WO1997000085A1 (fr) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Therapie genique de tumeurs solides au moyen d'interferons seuls ou associes a d'autres proteines immuno-effectrices
DE19608751B4 (de) 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
AU745958B2 (en) 1997-08-13 2002-04-11 Biontex Laboratories Gmbh Novel lipopolyamines, and the preparation and use thereof
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
WO1999036433A2 (fr) 1998-01-14 1999-07-22 Morphogenesis, Inc. Substances et methodes pour le traitement de maladies cancereuses
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
ATE482714T1 (de) 1998-02-20 2010-10-15 Univ Miami Modifizierter hitzeschockprotein-antigenpeptid- komplex
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
BR0001029A (pt) * 2000-04-10 2001-11-20 Fk Biotecnologia Ltda Processo de transformação de células tumorais
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN102014937A (zh) 2008-03-03 2011-04-13 迈阿密大学 基于异基因癌细胞的免疫治疗
EP2274001A4 (fr) 2008-03-20 2012-08-01 Univ Miami Vaccination par protéine de choc thermique gp96 et procédés d'utilisation
WO2016127015A1 (fr) 2015-02-06 2016-08-11 Heat Biologics, Inc. Vecteur co-exprimant un vaccin et des molécules co-stimulantes
EP3487999A4 (fr) * 2016-07-25 2020-05-20 Ascend Biopharmaceuticals Ltd Procédés de traitement d'un cancer
WO2018071405A1 (fr) 2016-10-11 2018-04-19 University Of Miami Vecteurs et cellules de vaccin pour immunité contre le virus zika
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130121910A (ko) * 2010-12-02 2013-11-06 온코세라피 사이언스 가부시키가이샤 Tomm34 펩티드 및 이를 포함한 백신
WO2019132594A1 (fr) * 2017-12-29 2019-07-04 한양대학교 산학협력단 Feuille cellulaire pour l'administration de gènes
KR20190082134A (ko) * 2017-12-29 2019-07-09 한양대학교 산학협력단 유전자 전달용 세포 시트

Also Published As

Publication number Publication date
FI954383A (fi) 1995-09-18
NO953684D0 (no) 1995-09-18
AU6427994A (en) 1994-10-11
CA2158655A1 (fr) 1994-09-29
HU9502720D0 (en) 1995-11-28
NZ263550A (en) 1996-12-20
HUT73383A (en) 1996-07-29
NO953684L (no) 1995-09-18
CZ241795A3 (en) 1996-04-17
FI954383A0 (fi) 1995-09-18
JPH08507921A (ja) 1996-08-27
PL311036A1 (en) 1996-01-22
WO1994021808A1 (fr) 1994-09-29
EP0689604A1 (fr) 1996-01-03
CN1119459A (zh) 1996-03-27

Similar Documents

Publication Publication Date Title
KR960701211A (ko) 암 백신을 제조하는 방법(process for preparing cancer vaccines)
NO903656L (no) Fremgangsmaate for fremstilling av 17beta-acyl-4-aza-5alfa-androst-1-en-3-oner.
KR960701058A (ko) 2-벤질-폴리사이클릭 구아닌 유도체 및 이의 제조방법(2-Benzyl-polycyslic guanine derivative and process for preparing them)
FI945856A (fi) Menetelmä level-off-DP-selluloosan valmistamiseksi
ITMI932443A0 (it) Processo per preparare perfluoropolietri
BR9306110A (pt) Processo para preparar metil éteres
EP0463624A3 (en) Process for preparing organopolysilanes
IT1245736B (it) Processo per preparare alfa-glicerofosforilcolina
NO920965D0 (no) Fremgangsmaate for fremstilling av etylen-alfa-olefinkopolymerer
NO901832L (no) Fremgangsmaate for fremstilling av polyketon.
CS324791A3 (en) Process for preparing kerebastin
KR970702922A (ko) 독소루비신의 제조방법(Process for preparing doxorubicin)
NO902861D0 (no) Naftylamino- og naftyloksypyridinaminer og beslektede forbindelser og fremgangsmaate for fremstilling derav.
IT1230798B (it) Procedimento di omologazione per preparare alcoli superiori.
ITMI922604A0 (it) Procedimento per preparare triazoloni
MX9101668A (es) Proceso para preparar derivados de 8-cloroquinolona
EP0465373A3 (en) Process for obtaining kappa-carrageens
FI951581A (fi) Menetelmä 9-aminokamptotesiinin valmistamiseksi
NO902890L (no) Fenoksypyridinaminer og beslektede forbindelser og fremgangsmaate for fremstilling derav.
NO903196D0 (no) Fremgangsmaate for fremstilling av 2-diazo-3-trisubstituerte silyloksy-3-butenoater.
IT1230097B (it) Procedimento per preparare perfluorosuccinilfluoruro.
TH7144EX (th) กรรมวิธีสำหรับเตรียม n-ซัลโฟนิล ยูเรีย
ITMI912059A1 (it) Procedimento per preparare perfluorovinileteri
ZA916490B (en) Footrot vaccine
ITMI912612A0 (it) 5-nitro-1-metil-imidazolil-3-terbutil-2-idrossi-5-metossi-fenil- carbinolo,processo per prepararlo e relative composizioni terapautiche

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid